Biking for Action Medical Research
Our co-founder and Director of Translational, Darcey Black, is planning to take part in the BiotechBikers “Catalyst” Charity Event, a 250-mile cycle ride from London to Bruges, on 8th to 10th May 2025. The event will raise funds for Action Medical Research. Action Medical Research (www.action.org.uk) is the leading UK charity dedicated to funding […]
Exploring the Potential of Inhalation Therapies for IPF: Lessons from Asthma
A few weeks ago, our updated review on the state of drug development in Idiopathic Pulmonary Fibrosis (IPF) was published in Drug Discovery Today. This update highlights the untapped potential of inhaled drug delivery in the treatment of IPF, a disease with poor prognosis and limited treatment options. It’s worth contrasting this therapeutic scenario with that […]
The Evolving Landscape of IPF Drug Discovery and Development
Idiopathic Pulmonary Fibrosis (IPF) remains one of the most challenging respiratory diseases to treat, characterized by progressive lung scarring and severely unpredictable disease progression. Despite high unmet clinical needs, the current standard of care—antifibrotic therapies nintedanib and pirfenidone—offers only modest benefits, with ongoing side effects that are a significant burden to patients. In our latest […]
Reflections from ERS
Having joined a wide range of sessions at the virtual ERS meeting last week, we were keen to share some of our reflections. Despite the virtual format there was still a huge amount of information, so we have decided to limit this to just 4 take-home messages that we came away with. What’s next in COPD? When working with […]